Should I buy or sell Adaptive Biotechnologies stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADPT shares. View ADPT analyst ratings or view top-rated stocks .

What is Adaptive Biotechnologies' stock price target for 2024?

6 brokerages have issued 1 year price objectives for Adaptive Biotechnologies' stock. Their ADPT share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $6.80 in the next year. This suggests a possible upside of 189.4% from the stock's current price. View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts .

How have ADPT shares performed in 2024?

Adaptive Biotechnologies' stock was trading at $4.90 on January 1st, 2024. Since then, ADPT stock has decreased by 52.0% and is now trading at $2.35. View the best growth stocks for 2024 here .

Are investors shorting Adaptive Biotechnologies?

Adaptive Biotechnologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,100,000 shares, an increase of 7.6% from the March 15th total of 8,460,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is presently 6.1 days. Approximately 6.6% of the shares of the stock are sold short. View Adaptive Biotechnologies' Short Interest .

When is Adaptive Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ADPT earnings forecast .

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.02. The company had revenue of $45.78 million for the quarter, compared to analyst estimates of $50.15 million. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative trailing twelve-month return on equity of 53.65%.

What ETFs hold Adaptive Biotechnologies' stock?

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM) . First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has Adaptive Biotechnologies issued on next quarter's earnings?

Adaptive Biotechnologies issued an update on its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million.

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com . Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , QUALCOMM (QCOM) , Johnson & Johnson (JNJ) , Advanced Micro Devices (AMD) , CrowdStrike (CRWD) , Home Depot (HD) , Inovio Pharmaceuticals (INO) , PayPal (PYPL) and Tesla (TSLA) .

When did Adaptive Biotechnologies IPO?

Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADPT

Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ADPT Stock Alerts

$2.34

-0.10 (-4.11%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.33
▼
$2.46
50-Day Range: $2.44
▼
$4.27
52-Week Range: $2.33
▼
$9.08

Volume: 2.78 million shs
Average Volume: 1.61 million shs
Market Capitalization: $338.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.80

Get Adaptive Biotechnologies alerts:

Adaptive Biotechnologies MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 189.4% Upside
$6.80 Price Target
Short Interest: Bearish
6.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.79
Upright™ Environmental Score
News Sentiment: 0.49
Based on 6 Articles This Week
Insider Trading: Selling Shares
$428,090 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.31) to ($1.06) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

203rd out of 919 stocks

Biological Products, Except Diagnostic Industry

24th out of 152 stocks

3.3

Analyst's Opinion

Consensus Rating
Adaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Adaptive Biotechnologies has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.57% of the float of Adaptive Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
Adaptive Biotechnologies has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Adaptive Biotechnologies has recently increased by 7.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adaptive Biotechnologies does not currently pay a dividend.
Dividend Growth
Adaptive Biotechnologies does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Adaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.
Environmental Sustainability
The Environmental Impact score for Adaptive Biotechnologies is -0.79.

3.0

News and Social Media Coverage

News Sentiment
Adaptive Biotechnologies has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.
Search Interest
13 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.
MarketBeat Follows
17 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 183% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $428,090.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders.
Percentage Held by Institutions
99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.31) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adaptive Biotechnologies is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adaptive Biotechnologies is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adaptive Biotechnologies has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ADPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADPT Stock News Headlines

April 17, 2024 | globenewswire.com

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

April 17, 2024 | americanbankingnews.com

Short Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Increases By 7.6%

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 16, 2024 | bizjournals.com

Adaptive Biotechnologies names new CFO, restructures business lines

April 13, 2024 | msn.com

Adaptive Foundation offers free fitness classes for veterans, first responders in Tyler

April 13, 2024 | americanbankingnews.com

Head to Head Contrast: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Ikena Oncology (NASDAQ:IKNA)

April 9, 2024 | msn.com

The Center for Adaptive Riding hosts open house for new location

April 4, 2024 | uk.investing.com

Adaptive Biotechnologies CFO resigns, successor named

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 2, 2024 | marketwatch.com

Adaptive Biotechnologies to Restructure Businesses After Review

April 2, 2024 | globenewswire.com

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

April 1, 2024 | msn.com

Center for Adaptive Riding hosts open house at new facility

March 30, 2024 | msn.com

Local family hosts ‘Adaptive Easter Egg Hunt’

March 28, 2024 | finance.yahoo.com

Netcracker Continues Its Support of the U.S. Paralympic Ski and Snowboard Team at Adaptive Spirit 2024

March 27, 2024 | investorplace.com

The 7 Best Penny Stocks to Buy in Q2 2024

March 27, 2024 | globenewswire.com

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

March 27, 2024 | finance.yahoo.com

Canada Adaptive Clothing Market to Reach US$ 79.08 Million by 2031, Rising at a CAGR of 8.7% | Report by CoherentMI

March 23, 2024 | msn.com

Adaptive surfers dazzle at Byron Bay as they push for acceptance into Paralympics

March 19, 2024 | finance.yahoo.com

March 16, 2024 | forbes.com

XBox Adaptive Controller Review: A Necessary Accessory

March 12, 2024 | sports.yahoo.com

Are algorithms going to revolutionize MTB suspension? RockShox releases new Flight Attendant with Adaptive Ride Dynamics

March 12, 2024 | tmcnet.com

Adaptive ML Raises $20M to Help Companies Build Unique GenAI Experiences

March 10, 2024 | msn.com

Boston-based film ‘American Fiction’ wins Oscar for Best Adaptive Screenplay

March 6, 2024 | msn.com

Adaptive Adventures returns to Marquette

March 1, 2024 | msn.com

Sweet victory: Bakersfield ARC Ball Hogs win basketball tournament in Adaptive Sports League

February 23, 2024 | msn.com

Adaptive skiing helps people with disabilities ski and compete at Snowbowl

February 22, 2024 | globenewswire.com

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

See More Headlines

Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ADPT
CUSIP: N/A
CIK: 1478320
Web: www.constructionpartners.net
Phone: (206) 659-0067
Fax: 206-659-0667
Employees: 709
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $6.80
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +178.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-225,250,000.00
Net Margins: -132.29%
Pretax Margin: -132.32%
Return on Equity: -53.65%
Return on Assets: -27.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.66
Quick Ratio: 4.50

Sales & Book Value

Annual Sales: $170.28 million
Price / Sales: 2.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.13 per share
Price / Book: 1.15

Miscellaneous

Outstanding Shares: 145,090,000
Free Float: 137,547,000
Market Cap: $354.02 million
Optionable: Optionable
Beta: 1.25

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Chad M. Robins M.B.A. (Age 50)
Co-Founder, CEO & Chairman
Comp: $1.19M
Ms. Julie Rubinstein (Age 52)
President & COO
Comp: $760.46k
Dr. Harlan S. Robins Ph.D. (Age 51)
Co-Founder & Chief Scientific Officer
Comp: $759.61k
Mr. Tycho W. Peterson (Age 50)
Chief Financial Officer
Comp: $539.73k
Mr. Kyle Piskel (Age 40)
VP & Principal Accounting Officer
Comp: $375.9k
Dr. Sharon Benzeno Ph.D. (Age 50)
Chief Commercial Officer of Immune Medicine
Comp: $671.29k
Mr. Christopher Carlson Ph.D.
Founder
Karina Calzadilla
Vice President of Investor Relations
Ms. Stacy L. Taylor (Age 64)
Senior VP, General Counsel & Corporate Secretary
Mr. Francis T. Lo (Age 43)
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptive Biotechnologies stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADPT shares.
View ADPT analyst ratings or view top-rated stocks.
What is Adaptive Biotechnologies' stock price target for 2024?: 6 brokerages have issued 1 year price objectives for Adaptive Biotechnologies' stock. Their ADPT share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $6.80 in the next year. This suggests a possible upside of 189.4% from the stock's current price.
View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts.
How have ADPT shares performed in 2024?: Adaptive Biotechnologies' stock was trading at $4.90 on January 1st, 2024. Since then, ADPT stock has decreased by 52.0% and is now trading at $2.35.
View the best growth stocks for 2024 here.
Are investors shorting Adaptive Biotechnologies?: Adaptive Biotechnologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,100,000 shares, an increase of 7.6% from the March 15th total of 8,460,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is presently 6.1 days. Approximately 6.6% of the shares of the stock are sold short.
View Adaptive Biotechnologies' Short Interest.
When is Adaptive Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ADPT earnings forecast.
How were Adaptive Biotechnologies' earnings last quarter?: Adaptive Biotechnologies Co. (NASDAQ:ADPT) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.02. The company had revenue of $45.78 million for the quarter, compared to analyst estimates of $50.15 million. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative trailing twelve-month return on equity of 53.65%.

What ETFs hold Adaptive Biotechnologies' stock?: ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).
What guidance has Adaptive Biotechnologies issued on next quarter's earnings?: Adaptive Biotechnologies issued an update on its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million.
What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?: 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Adaptive Biotechnologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).
When did Adaptive Biotechnologies IPO?: Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.
How do I buy shares of Adaptive Biotechnologies?: Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADPT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

Adaptive Biotechnologies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

ADPT Stock Price History

ADPT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ADPT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™